Iida Municipal Hospital.
Int J Psychiatry Clin Pract. 2003;7 Suppl 1:25-7. doi: 10.1080/13651500310000870.
Anhedonia and apathy are the main symptoms of depression generally associated with Parkinson's disease. Tricyclic antidepressants (TCA) and selective serotonin reuptake inhibitors (SSRI) have been used to treat depression associated with Parkinson's disease. However, the poor tolerance of TCA and the worsening of the motor function by SSRI have favoured other therapeutic approaches. Some studies have shown that agents stimulating the noradrenergic system were able to improve depression in parkinsonian patients. The serotonin and noradrenaline reuptake inhibitor, milnacipran, has become available recently in Japan. The aim of this study was to investigate the potential of milnacipran to alleviate depressive symptoms in patients suffering from Parkinson's disease, particularly the symptoms anhedonia and apathy.
快感缺失和淡漠是帕金森病患者常见的抑郁症状。三环类抗抑郁药（TCA）和选择性 5-羟色胺再摄取抑制剂（SSRI）已被用于治疗帕金森病相关的抑郁症。然而，TCA 的耐受性差和 SSRI 使运动功能恶化，这促使人们寻求其他治疗方法。一些研究表明，刺激去甲肾上腺素能系统的药物能够改善帕金森病患者的抑郁。5-羟色胺和去甲肾上腺素再摄取抑制剂米那普仑最近在日本上市。本研究旨在探讨米那普仑缓解帕金森病患者抑郁症状的潜力，特别是快感缺失和淡漠等症状。
